Institut Pasteur
Also known as: Centre Medical de l'Institut Pasteur | Director of the Institut Pasteur de Bangui, Central African Republic | Immunology Investigator, Pasteur Institut Paris | Institute Pasteur, Cambodia | Institute Pasteur Tunisia | Institut Pasteur | Institut Pasteur, Cambodia | Institut Pasteur Dakar | Institut Pasteur de Bangui | Institut Pasteur de Dakar | Institut Pasteur de Dakar, Senegal | Institut Pasteur de la Guyane | Institut Pasteur de Lille | Institut Pasteur de Lille - NutrInvest | Institut Pasteur de Madagascar | Institut Pasteur de Nouvelle-Calédonie | Institut Pasteur de Paris | Institut Pasteur de Tunis | Institut Pasteur du Cambodge | Institut Pasteur du Maroc | Institut Pasteur in Cambodia | Institut Pasteur in Madagascar (subject recruitment) | Institut Pasteur, Paris France | Institut Pasteur, Tunisia | Pasteur Institute, Ho Chi Minh City | Pasteur Institute of Ho Chi Minh City | Pasteur Institute of Iran, Tehran, Iran | Unité de Recherche et d'Expertise Epidémiologie des maladies émergentes, Institut Pasteur, Paris
Highest phase reached
Phase 4
First clinical trial
Aug 1, 2002Last known activity
Aug 30, 2025
Timeline
1880s
- Jun 1, 1887
Institut Pasteur— Founded
Drugs by trial phase (78 distinct, 68 trials)
Phase 4 (14 own, 0 via acquisition)
- artemisinin
- diphtheria, tetanus and whole cell pertussis vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- mebendazole
- hepatitis b vaccine (recombinant)
- quinvaxem
- primaquine
- yellow fever vaccine 17d strain
- inactivated influenza vaccine
- chloroquine
- bivalent oral polio vaccine (bopv), type 1 and type 3
- polio, inactivated poliovirus vaccine
- piperaquine
- dihydroartemisinin
Phase 3 (35 own, 0 via acquisition)
Phase 2 (10 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Communicable Diseases
- Diabetes Mellitus, Type 2
- Diphtheria
- Dysentery
- Dysentery, Bacillary
- Fever
- Glucose Intolerance
- Glucosephosphate Dehydrogenase Deficiency
- Haemophilus Infections
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- HIV Infections
- Hypertriglyceridemia
- Infections
- Inflammatory Bowel Diseases
- Influenza, Human
- Influenza in Birds
- Insulin Resistance
- Intestinal Diseases
- Leishmaniasis
- Leishmaniasis, Cutaneous
- Malaria
- Malaria, Falciparum
- Malaria, Vivax
- Malnutrition
- Melanoma
- Meningitis
- Meningitis, Cryptococcal
- Mucopolysaccharidosis III
- Obesity
- Poisoning
- Prediabetic State
- Scorpion Stings
- Syndrome
- Tetanus
- Tetany
- Whooping Cough
- Yellow Fever
Recent trials (50)
- NCT07207434CollaboratorPhase 2Aug 30, 2025
- NCT05922683CollaboratorPhase 2Jul 1, 2023
- NCT05501470Overall official - principal investigatorPhase 2Dec 31, 2022
- NCT05501470Lead sponsorPhase 2Dec 31, 2022
- NCT05608928Overall official - principal investigatorPhase 2Dec 1, 2022
- NCT04975178CollaboratorPhase 3Jul 31, 2022
- NCT05306093Reponsible party - principal investigatorN/AJan 7, 2022
- NCT05306093Lead sponsorN/AJan 7, 2022
- NCT05178667Lead sponsorN/AJan 6, 2022
- NCT05178667Reponsible party - principal investigatorN/AJan 6, 2022
- NCT05178667Overall official - principal investigatorN/AJan 6, 2022
- NCT05221346Lead sponsorN/ADec 13, 2021
- NCT05221346Reponsible party - principal investigatorN/ADec 13, 2021
- NCT05221346Overall official - principal investigatorN/ADec 13, 2021
- NCT05668065Lead sponsorPhase 3Nov 22, 2021
Details
- Founded
- Paris, FR Jun 1, 1887
- Last known activity
- Aug 30, 2025